Skip to main content

Table 1 Summary of ICI outcomes within the lung cancer cohort

From: Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Best Radiologic Response Category

n (%)

Complete response

1 (1)

Partial response

25 (34)

Stable disease

13 (18)

Progressive disease

27 (36)

Treatment < 6 weeks

8 (11)

Toxicity grade

n (%)

irAE G 0 or 1

42 (57)

irAE G 2–4

18 (24)

Unknown

14 (19)